
HeartFlow Inc (HTFL) Stock Forecast & Price Target
HeartFlow Inc (HTFL) Analyst Ratings
Bulls say
HeartFlow Inc. experienced significant growth, with approximately 48% worldwide FFR-CT volume growth translating into a notable revenue increase of 41% year-over-year, reaching $46.3 million in 3Q25. The company's gross margins improved to 76.8%, reflecting operational efficiency and strong demand for its FFR-CT coronary disease analysis software, while management highlights continued growth in coronary CT angiography adoption and new account acquisitions. Looking forward, HeartFlow is poised for sustainable revenue growth in the mid-20% range, driven by the expansion of its core business and potential future contributions from plaque analysis revenues.
Bears say
HeartFlow Inc. faces a significant negative outlook due to its ongoing pattern of substantial net losses, totaling $95.7 million in FY23 and $96.4 million in FY24, with expectations of continued losses in the foreseeable future. Additionally, the company relies heavily on healthcare providers adhering to specific guidelines for the utilization of its technology, raising concerns about the widespread adoption of its HeartFlow platform. Compounding these issues is the reimbursement risk; if third-party payors do not adequately cover the HeartFlow platform, or if changes further limit reimbursement, the company's financial stability and growth potential may be severely jeopardized.
This aggregate rating is based on analysts' research of HeartFlow Inc and is not a guaranteed prediction by Public.com or investment advice.
HeartFlow Inc (HTFL) Analyst Forecast & Price Prediction
Start investing in HeartFlow Inc (HTFL)
Order type
Buy in
Order amount
Est. shares
0 shares